Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q3 2021 Earnings Presentation

17 slides from Reata Pharmaceuticals's earnings presentation, Nov 8, 2021

  1. Slide 1: 3rd Quarter 2021 Financial Results and Update on Clinical Development Programs

    November 8, 2021 3rd Quarter 2021 Financial Results and Update on Clinical Development Programs Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda

  4. Slide 4: Bardoxolone in CKD

    Bardoxolone in CKD

  5. Slide 5: Regulatory Update on Bardoxolone for Patients with CKD Caused by Alport Syndrome

    Regulatory Update on Bardoxolone for Patients with CKD Caused by Alport Syndrome CKD: Chronic Kidney Disease; PDUFA: Prescription Drug User Fee Act; MAA: Marketing Authorization Application; PMDA: Pharmaceuticals and Medical Devices Agency

  6. Slide 6: Advisory Committee Preparations

    Advisory Committee Preparations FDA: U.S. Food and Drug Administration; KOL: Key Opinion Leader Submitted Advisory Committee meeting briefing book to FDA Working with external KOLs who will join us in our Advisory Committee meeting bullpen Completed mock Advisory Committee meetings with former panel

  7. Slide 7: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD

    FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD ADPKD: Autosomal Dominant Polycystic Kidney Disease; eGFR: estimated Glomerular Filtration Rate International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patients with ADPKD Primary endpoint: o

  8. Slide 8: Omaveloxolone in Friedreich's Ataxia

    Omaveloxolone in Friedreich’s Ataxia

  9. Slide 9: Regulatory Update on Omaveloxolone for Patients with Friedreich's Ataxia

    Regulatory Update on Omaveloxolone for Patients with Friedreich’s Ataxia NDA: New Drug Application; 1Per FDA’s discretion, subject to review

  10. Slide 10: Commercial Readiness Preparation

    Commercial Readiness Preparation

  11. Slide 11: Commercial Launch Preparation

    Commercial Launch Preparation Alport Syndrome: Completed Friedreich’s Ataxia: Re-Initiated

  12. Slide 12: ov ~ o ns] a =) ie) c o c a HBREATA.

    ov ~ o ns] a =) 2 ie) c o c a HBREATA.

  13. Slide 13: Q3 2021 Cash & Shares; Financial Guidance and Summary

    Q3 2021 Cash & Shares Cash $713.2M Total Shares Outstanding 36.4M 31.5M class A shares outstanding 4.9M class B shares outstanding 2021 Financial Guidance Based on our operational plans, we anticipate cash runway through mid-2024 Financial Summary 1Excludes stock-based compensation expenses; 2GAAP a

  14. Slide 14: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures

  15. Slide 15: Concluding Remarks

    Concluding Remarks

  16. Slide 16: Reata at a Glance

    Reata at a Glance NDA for bardoxolone in CKD caused by Alport syndrome under review AdCom meeting Dec 8, 2021; PDUFA date Feb 25, 2022 FALCON enrolled >450 patients; protocol to be amended Pre-NDA meeting for omaveloxolone in FA completed Plan to submit NDA during Q1 2022 Updated plan to initiate Ph

  17. Slide 17: Thank you

    Thank you

Reata Pharmaceuticals — Q3 2021 Earnings Presentation on 6ix